## 2 Materials and Methods  
### Cell Culture Conditions  
The effect of CAP in several adherent human cancer cell lines was studied, namely, melanoma (A375), extrahepatic bile duct carcinoma (TFK-1), osteosarcoma (MNNG-HOS), colon carcinoma (WiDr), prostate cancer (PC3 and LnCap), urinary bladder grade 3 carcinoma (HT-1376), esophageal adenocarcinoma (OE19), hormonal receptor positive breast cancer (MCF7), triple-negative breast cancer (HCC1806), lung cancer (H1299), and endometrial cancer (ECC-1). A cell line of human fibroblasts (HFF-1) was also evaluated. The cell lines were purchased from the American Type Culture Collection or from the European Collection of Authenticated Cell Cultures. All cell lines were cultured under standard cell culture conditions (37 \({}^{\circ}\)C, 5% CO\({}_{2}\)). TKF-1 cells were cultured with Roswell Park Memorial Institute (RPMI-1640, Sigma Aldrich\({}^{\circledR}\), St. Louis, MO, USA) medium and supplemented with 15% fetal bovine serum (FBS, Sigma Aldrich\({}^{\circledR}\), St. Louis, MO, USA). LnCap, HCC1806, and ECC-1 were cultured with the same medium, however, it was supplemented with 10% FBS, while PC3 was supplemented with 5% FBS. A375, MNNG-HOS, HT-1376, H1299, MCF, WiDr, OE19, and HFF1 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM, Sigma Aldrich\({}^{\circledR}\), St. Louis, MO, USA). A375, MNNG-HOS, and OE19 were supplemented with 5% FBS. HT-1376, H1299, MCF, and WiDr cells were cultured with the same medium but were supplemented with 10% FBS. HFF1 was supplemented with 15% FBS. All media contained 1% of penicillin-streptomycin solution (Gibco, Thermo Fisher Scientific, MA, USA). Cells were plated with concentrations between 50,000 and 250,000 cells/mL (Table 3) in 48-multi-well plates (Sarstedt, Newton, NC, USA) with a media volume of 200 \(\mu\)L per well and incubated for 24 h. \begin{table}
\begin{tabular}{c c c c c c} \hline \hline
**Cell Line** & \begin{tabular}{c} **Cells Plated** \\ **(Cells/mL)** \\ \end{tabular} & **Organ** & **Histology** & \begin{tabular}{c} **Culture** \\ **Medium** \\ \end{tabular} & **MTT (IT50 (s))** & **SRB (IT50 (s))** \\ \hline A375 & 100,000 & Skin & Melanoma & DMEM 5\% & \(32.1\pm 7.1\) & \(31.8\pm 1.5\) \\ \hline OE19 & 100,000 & Esophagus & Adenocarcinoma & DMEM 5\% & \(68.9\pm 9.0\) & nc. \\ \hline HT1376 & 80,0000 & Urinary bladder & \begin{tabular}{c} Translational \\ carcinoma grade 3 \\ \end{tabular} & DMEM 10\% & \(34.6\pm 3.7\) & \(35.0\pm 3.6\) \\ \hline MNNG/HOS & 50,000 & Bone & Osteosarcoma & DMEM 5\% & \(33.1\pm 4.6\) & \(66.8\pm 5.5\) \\ \hline TFK-1 & 80,000 & Extra-hepatic bile duct & Carcinoma & RPMI 15\% & \(30.5\pm 3.2\) & \(44.2\pm 7.9\) \\ \hline PC3 & 100,000 & Prostate (derived from & \begin{tabular}{c} Adenocarcinoma \\ bone) \\ \end{tabular} & RPMI 5\% & \(25.4\pm 4.0\) & nc. \\ \hline WIDR & 50,000 & Colon & Adenocarcinoma & DMEM 10\% & nc. & \(50.7\pm 6.3\) \\ \hline LNCAP & 100,000 & \begin{tabular}{c} Prostate (derived from left \\ supraclaviular lymph \\ node) \\ \end{tabular} & Adenocarcinoma & RPMI 10\% & \(19.0\pm 2.5\) & \(40.2\pm 10.9\) \\ \hline ECC-1 & 100,000 & Endometrium & Adenocarcinoma & RPMI 10\% & \(36.6\pm 4.1\) & \(48.9\pm 13.6\) \\ \hline H1299 & 100,000 & Lung (derived from & \begin{tabular}{c} Large cell \\ lymph node) \\ \end{tabular} & DMEM 10\% & \(46.4\pm 6.2\) & \(35.3\pm 5.0\) \\ \hline MCF-7 & 100,000 & \begin{tabular}{c} Breast (derived from \\ Pleural effusion) \\ \end{tabular} & \
\begin{tabular}{c} Invasive ductal \\ carcinoma \\ \end{tabular} & DMEM 10\% & \(65.6\pm 7.9\) & \(22.4\pm 4.7\) \\ \hline HCC 1806 & 100,000 & Breast &
\begin{tabular}{c} Squamous cell \\ breast carcinoma, \\ acantholytic variant \\ \end{tabular} & RPMI 10\% & \(69.4\pm 9.3\) & \(49.8\pm 10.0\) \\ \hline HFF-1 & 250,000 & Connective tissue & Fibroblasts & DMEM 15\% & \(61.5\pm 2.1\) & nc. \\ \hline \hline \end{tabular}
\end{table} 
Table 3: Comparison of different characteristics of treated cell lines and the effect of treatment observed.